Yes. In a phase 2b randomized trial, a single dose of MM120 reduced generalized anxiety disorder symptoms at 4 weeks versus placebo, showing a dose response.
The 100 µg and 200 µg doses produced statistically significant improvements on the Hamilton Anxiety Rating Scale compared with placebo, by about 5 and 6 points respectively. The 25 µg and 50 µg doses were not significant.
Considering efficacy and tolerability within this study, 100 µg appears most practical. It showed rapid and sustained improvements while producing fewer dose-related acute effects than 200 µg. Common short-term effects were visual perceptual changes, nausea, and headache, with higher rates at higher doses.
These findings come from a single controlled study without extensive psychotherapy, and blinding can be difficult in psychedelic trials. In short, one MM120 session reduced GAD symptoms, with 100 µg looking like the best balance in this trial.